Table 2.

Clinicopathologic characteristics of patients. Clinicopathologic characteristics of healthy controls and patients with cervical cancer. CCRT: concurrent chemoradiotherapy; aCRT: adjuvant chemoradiotherapy; pCRT: primary chemoradiotherapy. HDR: high dose-rate

Patients with cervical cancer
Participants (n)	Healthy controls (n = 115)	Healthy controls subgroup for IF (n = 40/115)	Patients subgroup for IF (n = 40/115)	Treated with surgery (n = 57)	Treated with CCRT (n = 58)
					aCRT (n = 36)	pCRT (n = 22)
Age of diagnosis/participation (mean ± SD)	53.0 ± 8.6	52.0 ± 8.9	50.3 ± 11.0	50.2 ± 11.8	51.0 ± 13.4	55.1 ± 8.6
Diagnosis:	/	/
Squamous cell carcinomas (n = 88)			n = 29 (33%)	n = 44 (50%)	n = 24 (27%)	n = 20 (23%)
Adenocarcinomas (n = 27)			n = 11 (41%)	n = 13 (48%)	n = 12 (44%)	n = 2 (8%)
Stage (FIGO)	/	/
Stage I: n = 47 (40%)				n = 39 (33%)	n = 8 (7%)	n = 0 (0%)
I			n = 1	n = 1
IA			n = 2	n = 2
IA1			n = 5	n = 11
IA2			n = 1	n = 3
IB			n = 1	n = 4
IB1			n = 7	n = 16	n = 6
IB2			n = 2	n = 2	n = 2
Stage II: n = 42 (37%)				n = 18 (16%)	n = 18 (16%)	n = 6 (5%)
II			n = 1	n = 3
IIA			n = 1	n = 11
IIA1			n = 3		n = 2
IIA2			n = 3	n = 4	n = 3	n = 1
IIB					n = 13	n = 5
Stage III: n = 16 (14%)			n = 3		n = 10 (9%)	n = 6 (5%)
III					n = 3	n = 1
IIIA			n = 3			n = 2
IIIB					n = 6	n = 1
IIIC					n = 1	n = 2
Stage IV: n = 10 (9%)						n = 10 (9%)
IV			n = 3			n = 4
IVA			n = 1			n = 3
IVB			n = 3			n = 3
Nodal stage	/	/
N0: n = 68 (59%)			n = 23	n = 56 (48%)	n = 1 (1%)	n = 11 (10%)
N1: n = 46 (40%)			n = 17	n = 0 (0%)	n = 35 (30%)	n = 11 (10%)
NX: n = 1 (1%)			n = 0	n = 1 (1%)	n = 0 (0%)	n = 0 (0%)
Chemoradiotherapy
External beam irradiation					n = 36 (31%)	n = 8 (7%)
mean dose in Gray					51.7	53.6
range					50.4–59	45-59.9
intracavitary HDR brachytherapy						n = 14 (12%)
mean dose in Gray						21.6
range						10–28